Darrel P. Cohen

Suggest Changes
Learn More
PURPOSE Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor alpha (PDGFRA) kinases, which are imatinib targets. Sunitinib, which targets KIT,(More)
PURPOSE To analyze final long-term survival and clinical outcomes from the randomized phase III study of sunitinib in gastrointestinal stromal tumor patients after imatinib failure; to assess(More)
e21113 Background: Common side effects of tyrosine kinase inhibitors (TKIs) such as SU include HFS and related skin toxicities. SU is a multitargeted inhibitor of VEGFR, PDGFR and KIT, and is(More)
13061 Background: VEGF Trap is a potent angiogenesis inhibitor comprising portions of human VEGF receptor VEGFR1 (Flt-1) and VEGFR2 (KDR) extracellular domains fused to the Fc portion of human IgG.(More)
PURPOSE To evaluate sunitinib activity and potential cellular and molecular correlates in gastrointestinal stromal tumor (GIST) patients after imatinib failure, in addition to assessing the safety(More)